jRCT2051250035尚未招募不适用
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2A-MC-GZP2: Participants With Obesity or Overweight and Type 2 Diabetes (J2A-MC-GZP2 )
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 600
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Have body mass index (BMI) >=25 kilograms per square meter (kg/m2) at screening
- •Have type 2 diabetes
- •Have hemoglobin A1c (HbA1c) >=7% and <=10% at screening
- •Have a history of at least one unsuccessful dietary effort to lose body weight
排除标准
- •Have type 1 diabetes
- •Have an unstable body weight within 90 days prior to screening
- •Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- •Have acute or chronic hepatitis or pancreatitis
- •Are taking other medications or alternative remedies to manage weight loss
结局指标
主要结局
-
Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 40
次要结局
未报告次要终点
研究者
相似试验
尚未招募
不适用
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
(J2A-MC-GZP1)jRCT2051250032Eli Lilly Japan K.K.600
已完成
3 期
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskOverweight or ObesityOverweightCardiovascular DiseasesType 2 DiabetesChronic Kidney DiseaseObesityNCT05803421Eli Lilly and Company2,749
已完成
3 期
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminType 2 DiabetesNCT06045221Eli Lilly and Company1,698
已完成
3 期
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneType 2 DiabetesNCT05971940Eli Lilly and Company559
已完成
3 期
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminType 2 DiabetesNCT06192108Eli Lilly and Company962